tirzepatide ema Fake weight-loss drug sales surge in Europe – POLITICO Is Mounjaro a Steroid? Understanding

General PA criteria include: BMI threshold: BMI 30 (obesity), or BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease) Documentation of medical necessity: Clinical notes confirming obesity diagnosis, comorbidities, and treatment rationale from a licensed provider Prior lifestyle program participation: Many plans require documentation of participation in a structured diet and exercise program for a defined period (typically 36 months) before GLP-1 medications are authorized Non-diabetic indication: For Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide weight loss dose), the weight management indication must be documented separately from diabetes management Step therapy: Some Cigna plans may require an oral agent (such as phentermine or Contrave) trial before authorizing higher-cost GLP-1 medications Ongoing authorization: GLP-1 PA approvals are typically renewable annually and may require documentation of 5% body weight reduction to continue coverage Klarity Healths clinical team may assist with the prior authorization process

Zhao, The effects of advanced glycation end-products on skin and potential anti-glycation strategies

This leads to decreased hunger, which helps individuals consume fewer calories

Claire Turnbull is a registered nutritionist with an honours degree in dietetics, a wellbeing educator and author.

The roadmap makes it easier for Cincinnati residents to follow their plan with confidence

Cardiovascular events among people with type 2 diabetes reduced by quick use of statins New study uncovers key muscle pathways behind insulin resistance in type 2 diabetes Cardiovascular events among people with type 2 diabetes reduced by quick use of statins The findings underline the growing preference for long-acting, once-weekly injections and dual-action drugs like tirzepatide, which activates both GIP and GLP-1 receptors